BioNTech SE ADR rises Friday, outperforms market
BioNTech SE ADR closed $8.64 short of its 52-week high ($131.49), which the company achieved on September 17th.
Truist Financial Issues a Buy Rating on BioNTech SE (BNTX)
In a report released today, Asthika Goonewardene from Truist Financial assigned a Buy rating to BioNTech SE (BNTX – Research Report). The ...
Goldman Sachs Sticks to Their Buy Rating for BioNTech SE (BNTX)
In a report released today, Chris Shibutani from Goldman Sachs maintained a Buy rating on BioNTech SE (BNTX – Research Report), with a price ...
BioNTech Positioned For Solid Growth Amid Oncology Transition: Analyst
Truist initiated coverage on BioNTech SE (NASDAQ:BNTX), a famed COVID-19 vaccine maker, in collaboration with Pfizer Inc ...
Fintel on MSN6d
Truist Securities Initiates Coverage of BioNTech SE - Depositary Receipt () (BNTX) with Buy Recommendation
Fintel reports that on January 10, 2025, Truist Securities initiated coverage of BioNTech SE - Depositary Receipt () ...
BioNTech SE: BioNTech Provides Business and Pipeline Updates at 43rd Annual J.P. Morgan Healthcare Conference
Executing in oncology with investigational BNT327/PM8002 combinations and mRNA cancer immunotherapy candidates as pan-tumor treatment approaches BioNTech aims to develop BNT327/PM8002 as a next-genera ...
BioNTech Provides Business and Pipeline Updates at 43rd Annual J.P. Morgan Healthcare Conference
Executing in oncology with investigational BNT327/PM8002 combinations and mRNA cancer immunotherapy candidates as pan-tumor treatment approaches BioNTech aims to develop BNT327/PM8002 as a next-genera ...
Nasdaq5d
Truist Securities Initiates Coverage of BioNTech SE - Depositary Receipt () (BRSE:22UA) with Buy Recommendation
Fintel reports that on January 10, 2025, Truist Securities initiated coverage of BioNTech SE - Depositary Receipt () (BRSE:22UA) with a Buy recommendation. There are 447 funds or institutions ...
BioNTech (NASDAQ:BNTX) Earns Buy Rating from Analysts at Truist Financial
Truist Financial initiated coverage on shares of BioNTech (NASDAQ:BNTX – Free Report) in a research report released on Friday morning, Marketbeat.com reports. The firm issued a buy rating and a ...